You are here
Basal Insulin Analogues for Primary Care Physicians
for Primary Care Physicians
In this course, you will learn about the importance of tight glycaemic control for the prevention of long-term complications and learn to differentiate between the various insulin treatments based on their duration of action. The course will provide the rationale and safety profile for new basal insulin analogues used to control HbA1c and help you identify and manage patients for whom this treatment would be a viable option.
Summary of existing guidelines on insulin initiation and intensification in patients with type 2 diabetes
This interactive table provides an overview of the most recent recommendations from the four important diabetes guidelines (ADA-EASD, IDF, IDF for elderly, NICE) on glycemic targets, hypoglycemia, and insulin initiation and intensification strategies. It also contains information on new basal insulin treatments and their fixed-ratio combinations, such as approval status, recommended dosing, PK/PD profile and their clinical efficacy and safety outcomes. Table 1 provides an overview of the different glycaemic targets (HbA1c, FPG and PPG) mentioned in the guidelines with additional information on how to patients to reach those glycaemic targets.
Table 2 summarizes recommendations regarding hypoglycaemia, insulin treatment initiation and intensification, plus available basal insulin therapies. It also gives advice on how PCPs can manage patients with different co-morbidities and backgrounds.
Table 3 gives an overview of the new basal insulin regimens including their PK/PD characteristics, clinical efficacy and safety data.
You can obtain supplementary information on the guidelines and regimens with the help of interactive features; explore the interactive features within the table by tapping the green cells.
In this animated e-learning module we discuss new insulin therapies and their effect on glycaemic control and hypoglycaemia. The module was developed together with Professor Stewart B. Harris and focuses on the new longer-acting basal insulin analogues insulin degludec and insulin glargine 300 units/mL.
In this webcast, Professor Cos explains the working mechanism of long-acting basal insulin analogues and discusses their use in clinical practice.